Aegerion Pharmaceuticals Inc (AEGR)

AEGR (NASDAQ:Drugs)
$34.30
pos +1.52
+4.64%
Today's Range: 32.47 - 34.67 | AEGR Avg Daily Volume: 1,002,000
Last Update: 10/30/14 - 1:40 PM EDT
Volume: 795,949
YTD Performance: -53.81%
Open: $32.55
Previous Close: $32.78
52 Week Range: $26.25 - $101.00
Oustanding Shares: 29,547,119
Market Cap: 995,442,439
6-Month Chart
TheStreet Ratings Grade for AEGR
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 7 7
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.25 1.25 1.25 1.25
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -19.25
Price Earnings Comparisons:
AEGR Sector Avg. S&P 500
-19.25 0.00 27.09
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.05% -64.87% 132.32%
GROWTH 12 Mo 3 Yr CAGR
Revenue 0.00 0.00 0.00
Net Income 0.00 3.44 0.00
EPS 0.00 -0.57 0.00
Earnings for AEGR:
EBITDA -0.06B
Revenue 0.05B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $-0.18 $0.05 $-0.95 $1.64
Number of Analysts 6 5 6 6
High Estimate $-0.10 $0.15 $-0.64 $3.40
Low Estimate $-0.23 $-0.14 $-1.22 $0.54
Prior Year $-0.43 $-0.14 $-2.19 $-0.95
Growth Rate (Year over Year) 59.30% 135.71% 56.62% 272.98%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Charting setups in Myriad Genetics, Clovis Oncology and Aegerion Pharma.
Bearish
Mar 28, 2014 | 8:03 AM EDT
AEGR cut its number, Jefferies said. Driven by lowered revisions on Juxtapid sales. $80 price target and Buy rating. 
Bullish
Jun 12, 2013 | 8:26 AM EDT
AEGR price target was raised to $88, J.P. Morgan said. Encouraging physician feedback and the recent approval recommendation for Lojuxt...
Bullish
Dec 27, 2012 | 7:54 AM EST
Shares of AEGR now seen reaching $29, Jefferies said. Juxtapid approval. Buy rating.

Adam Feuerstein, Sr. Columnist for TheStreet, says three big FDA drug approval decisions are the next big things to watch in biotech.

Columnist Conversations

The Fibocall: Twitter updated from October 28 "All is not lost, though, as the stock is about to enter the bou...
The Fibocall: Amazon updated from October 24 (DAY 1) "Readers of The Fibocall know that we like to examine sto...
Gilead Sciences (GILD) bouncing back strongly after a bit of a sell-off yesterday after earnings report after ...
Carley, I could not disagree more on the value of the CFTC data. The numbers cannot be pooled on a cross-sect...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.